Physiological effects of high-flow nasal cannula therapy in preterm infants.


Journal

Archives of disease in childhood. Fetal and neonatal edition
ISSN: 1468-2052
Titre abrégé: Arch Dis Child Fetal Neonatal Ed
Pays: England
ID NLM: 9501297

Informations de publication

Date de publication:
Jan 2020
Historique:
received: 30 12 2018
revised: 27 04 2019
accepted: 03 05 2019
pubmed: 28 5 2019
medline: 24 12 2019
entrez: 25 5 2019
Statut: ppublish

Résumé

High-flow nasal cannula (HFNC) therapy is increasingly used in preterm infants despite a paucity of physiological studies. We aimed to investigate the effects of HFNC on respiratory physiology. A prospective randomised crossover study was performed enrolling clinically stable preterm infants receiving either HFNC or nasal continuous positive airway pressure (nCPAP). Infants in three current weight groups were studied: <1000 g, 1000-1500 g and >1500 g. Infants were randomised to either first receive HFNC flows 8-2 L/min and then nCPAP 6 cm H A total of 44 preterm infants, birth weights 500-1900 g, were studied. Increasing flows from 2 to 8 L/min significantly increased pEEP (mean 2.3-6.1 cm H HFNC therapy produces clinically significant pEEP with large variability at higher flow rates. Highest pressures were observed in infants weighing <1000 g. Flow, weight and mouth position are all important determinants of pressures generated. Reductions in pEECO

Identifiants

pubmed: 31123057
pii: archdischild-2018-316773
doi: 10.1136/archdischild-2018-316773
pmc: PMC6951230
doi:

Substances chimiques

Carbon Dioxide 142M471B3J
Oxygen S88TT14065

Types de publication

Journal Article Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

87-93

Subventions

Organisme : Medical Research Council
ID : MR/M008797/1
Pays : United Kingdom

Informations de copyright

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: ZL, ACF, SH, SG and CJO’B: none. MB: not related to this work: investigator-led research grants from Pfizer and Roche Diagnostics; speaker fees paid to Newcastle University from Novartis, Roche Diagnostics and TEVA. Travel expenses to educational meeting Boehringer Ingelheim and Vertex Pharmaceuticals.

Références

J Pediatr. 2016 Nov;178:309
pubmed: 27522445
J Perinatol. 2006 Aug;26(8):476-80
pubmed: 16688202
Pediatrics. 2008 Jan;121(1):82-8
pubmed: 18166560
ERJ Open Res. 2016 Nov 24;2(4):
pubmed: 28053968
J Appl Physiol (1985). 2017 Jan 1;122(1):191-197
pubmed: 27856714
Arch Dis Child Fetal Neonatal Ed. 2016 Jul;101(4):F371-2
pubmed: 27173417
J Appl Physiol (1985). 2013 Apr;114(8):1058-65
pubmed: 23412897
J Pediatr. 2009 Feb;154(2):177-82
pubmed: 18760803
Cochrane Database Syst Rev. 2016 Feb 22;2:CD006405
pubmed: 26899543
Intensive Care Med. 2013 Jun;39(6):1088-94
pubmed: 23494016
J Intensive Care Med. 2009 Sep-Oct;24(5):323-8
pubmed: 19703816
Pediatr Pulmonol. 2011 Jan;46(1):67-74
pubmed: 21171186
J Appl Physiol (1985). 2015 Jun 15;118(12):1525-32
pubmed: 25882385
Neonatology. 2018;113(3):235-241
pubmed: 29393237
Arch Dis Child Fetal Neonatal Ed. 2017 Mar;102(2):F173-F175
pubmed: 28213557
Acta Paediatr. 2014 Sep;103(9):898-903
pubmed: 24844683
N Engl J Med. 2016 Sep 22;375(12):1142-51
pubmed: 27653564
Crit Care Res Pract. 2016;2016:8041967
pubmed: 27375901
J Perinatol. 2007 Dec;27(12):772-5
pubmed: 17762844
Pediatr Pulmonol. 2017 Jun;52(6):792-798
pubmed: 28165671
Respir Med. 2009 Oct;103(10):1400-5
pubmed: 19467849
J Perinatol. 2008 Jan;28(1):42-7
pubmed: 17989697
Am J Respir Crit Care Med. 2017 May 1;195(9):1207-1215
pubmed: 27997805
Pediatrics. 2001 May;107(5):1081-3
pubmed: 11331690
Pediatrics. 2015 Sep;136(3):542-53
pubmed: 26283781
Eur Respir J. 2018 May 30;51(5):
pubmed: 29724917
J Perinatol. 2008 Nov;28(11):779-81
pubmed: 18974751
Crit Care Med. 2017 Dec;45(12):1981-1988
pubmed: 28857852
J Appl Physiol (1985). 2017 Jan 1;122(1):82-88
pubmed: 27815367
Pediatr Emerg Care. 2012 Nov;28(11):1179-84
pubmed: 23114244
Arch Dis Child Fetal Neonatal Ed. 2014 Jul;99(4):F315-20
pubmed: 24786469
J Pediatr. 2016 Jun;173:50-55.e1
pubmed: 27004673

Auteurs

Zheyi Liew (Z)

Paediatric Respiratory Medicine, Great North Children's Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK.

Alan C Fenton (AC)

Newcastle Neonatal Service, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
Newcastle University, Newcastle upon Tyne, UK.

Sundeep Harigopal (S)

Newcastle Neonatal Service, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
Newcastle University, Newcastle upon Tyne, UK.

Saikiran Gopalakaje (S)

Paediatric Respiratory Medicine, Great North Children's Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK.

Malcolm Brodlie (M)

Paediatric Respiratory Medicine, Great North Children's Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK.

Christopher J O'Brien (CJ)

Paediatric Respiratory Medicine, Great North Children's Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH